Moreover, PI3K activation did not serve as a predictive marker for the sensitivity of ovarian clear cell carcinoma investigated in Japanese patients cohort to PIK3CA/AKT/mTOR inhibitors [71]. This evidence concerns the gene MTOR and ovarian clear cell cancer.